Applicant: Leif Andersson et al.

Serial No. : 09/826,581 Filed : April 5, 2001 Page : 5 of 11

THE PARTY OF THE PROPERTY OF THE PARTY OF TH

In the claims:

Please amend the claims as follows:

1. (Currently amended) An isolated nucleic acid comprising a human PRKAG3 sequence, wherein said human PRKAG3 sequence comprises a nucleotide sequence variant and nucleotides flanking said sequence variant, wherein said nucleotide sequence variant is at a position selected from the group consisting of nucleotide 230 of SEQ ID NO:5, nucleotide 559 of SEQ ID NO:5, nucleotide 642 of SEQ ID NO:3, and nucleotide 1037 of SEQ ID NO:5, and wherein said isolated nucleic acid is at least 15 base pairs in length.

Attorney's Docket No.: 11145-007001

- 2. (Original) The nucleic acid of claim 1, wherein said nucleotide sequence variant is associated with a metabolic disease.
- 3. (Original) The nucleic acid of claim 2, wherein said metabolic disease is diabetes or obesity.
 - 4. (Cancelled)
 - 5. (Cancelled)
- 6. (Currently amended) The nucleic acid of elaim 4 claim 1, wherein said exon 3 nucleotide sequence variant comprises at nucleotide 230 is a substitution of a guanine for a cytosine at nucleotide 230.
- 7. (Currently amended) The nucleic acid of elaim 4 claim 1, wherein said exon 4 nucleotide sequence variant comprises at nucleotide 559 is a substitution of a thymine for a cytosine at nucleotide 550.
- 8. (Currently amended) The nucleic acid of elaim 4 claim 1, wherein said exon 10 nucleotide sequence variant emprises at nucleotide 1037 is a substitution of a thymine for a cytosine at nucleotide 1037.

Applicant: Leif Andersson et al. Attorney's Docket No.: 11145-007001

Serial No.: 09/826,581 Filed: April 5, 2001

Page : 6 of 11

ender and a second control of the co

9. (Cancelled)

10. (Cancelled)

11. (Currently amended) The nucleic acid of claim 1, wherein said PRKAG3 nucleic acid sequence encodes an AMP-activated protein kinase γ 3 subunit polypeptide, said polypeptide comprising an amino acid sequence variant.

- 12. (Currently amended) The nucleic acid of claim 11, wherein said amino acid sequence variant comprises is a substitution of an alanine residue for a proline residue at amino acid 71 of SEQ ID NO:6.
- 13. (Currently amended) The nucleic acid of claim 11, wherein said amino acid sequence variant emprises is a substitution of a tryptophan residue for an arginine residue at amino acid 340 of SEQ ID NO:6.

14-18. (Cancelled)

19. (New) The nucleic acid of claim 1, wherein said nucleotide sequence variant at nucleotide 642 is a substitution of a guanine for a cytosine.